Cargando…
Mitomycin C hypoxic pelvic perfusion for unresectable recurrent rectal cancer: pharmacokinetic comparison of surgical and percutaneous techniques
ABSTRACT: Patients with unresectable recurrent rectal cancer that progresses after standard and multi-modular treatments are candidates for hypoxic pelvic perfusion. Hypoxic pelvic perfusion can be performed using a surgical or percutaneous approach. The aim of this study was to examine whether the...
Autores principales: | Guadagni, Stefano, Fiorentini, Giammaria, Clementi, Marco, Palumbo, Paola, Mambrini, Andrea, Masedu, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Milan
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591364/ https://www.ncbi.nlm.nih.gov/pubmed/28791628 http://dx.doi.org/10.1007/s13304-017-0480-6 |
Ejemplares similares
-
Multidisciplinary palliation for unresectable recurrent rectal cancer: hypoxic pelvic perfusion with mitomycin C and oxaliplatin in patients progressing after systemic chemotherapy and radiotherapy, a retrospective cohort study
por: Guadagni, Stefano, et al.
Publicado: (2019) -
Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability
por: Guadagni, Stefano, et al.
Publicado: (2017) -
MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study
por: Guadagni, Stefano, et al.
Publicado: (2017) -
Circulating tumour cell gene expression and chemosensitivity analyses: predictive accuracy for response to multidisciplinary treatment of patients with unresectable refractory recurrent rectal cancer or unresectable refractory colorectal cancer liver metastases
por: Guadagni, Stefano, et al.
Publicado: (2022) -
Precision oncotherapy based on liquid biopsies in multidisciplinary treatment of unresectable recurrent rectal cancer: a retrospective cohort study
por: Guadagni, Stefano, et al.
Publicado: (2019)